MétaCan
Menu
← Back to cohort
Record W7133058243

Combination Chemotherapy and In vivo Modeling of BRCA-deficient, High-grade Serous Ovarian Cancer

2020· dissertation· W7133058243 on OpenAlexaff
Yen Ting Shen

Bibliographic record

VenueTSpace · 2020
Typedissertation
Language
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsUniversity of Toronto
FundersCongressionally Directed Medical Research ProgramsU.S. Department of Defense
KeywordsOvarian cancerCarboplatinOlaparibPARP inhibitorSerous fluidSynthetic lethalityIn vivoCancerBRCA mutation
DOInot available

Abstract

fetched live from OpenAlex

Ovarian cancer is the most fatal cancer in women with over 60% of patients succumbing to the disease. Mutations in a number of homologous recombination repair genes have been implicated in hereditary ovarian and breast cancer. Specifically, over half of ovarian cancer cases exhibit BRCA-deficiency by either germ line or somatic mutation, or epigenetic silencing. The importance of BRCA-deficiency is highlighted in its association with increased platinum sensitivity. Novel therapeutics such as PARP inhibitors have also been developed by exploiting the synthetic lethal phenotype of BRCA inactivation and PARP inhibition. However over 80% of patients still relapse with resistant disease. Therefore, strategies for more effective treatment are needed. The aim of this thesis was to investigate a chemotherapeutic ratiometric approach for treatment of ovarian cancer and provide a relevant pre-clinical model for evaluation of new therapeutic entities. The combination of carboplatin and olaparib resulted in profound synergism in BRCA-deficient high-grade serous ovarian cancer cell lines when carboplatin was administered at a higher molar ratio relative to olaparib. The combination achieved effective cytotoxicity by inducing greater DNA damage than either of the drugs alone. Synergism of carboplatin-olaparib combinations was also observed in a subset of BRCA-proficient cell lines, suggesting a potential for broader therapeutic applications. To further investigate the impact of BRCA status on therapeutic efficacy, a bioluminescent, BRCA-deficient xenograft model was developed. The model demonstrated characteristics resembling the disease clinically, including high disseminative tumor pattern, ascites production, and platinum sensitivity. Bioluminescent imaging as a means of non-invasion tumor monitoring correlated well with disease burden. Lastly, a systematic literature search identified potential limitations in utilization of bioluminescent imaging techniques in animal models. The correlation between bioluminescent signal and tumor burden is affected by many experimental aspects and it is difficult to identify a general limiting factor. Nonetheless, consideration must be given to methods of tumor measurement, heterogeneity of tumor cell population, and the location of the xenograft when developing the model. Overall, results presented herein provide encouraging data on the utilization of synergistic combinations and a valuable pre-clinical model for evaluation of such combinations for ovarian cancer treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.033
GPT teacher head0.357
Teacher spread0.323 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueTSpace→Same topicPARP inhibition in cancer therapy→French-language works237,207→